Genmab Announces Submission of U.S. & EU Regulatory Applications Seeking Approval of DARZALEX® (Daratumumab) Split Dosing Regimen
August 08, 2018 07:57 ET
|
Genmab A/S
Media Release sBLA & Type II Variation submitted to U.S. FDA and the EMA respectively, seeking approval of split dosing regimen for DARZALEXApplications seek to update...
CHMP Issues Positive Opinion Recommending DARZALEX® (daratumumab) for Front Line Multiple Myeloma
July 27, 2018 08:28 ET
|
Genmab A/S
Company Announcement CHMP issued positive opinion for DARZALEX for front line multiple myelomaFinal decision from European Commission expected in the coming monthsOpinion based on...
Genmab Announces Net Sales of DARZALEX® (daratumumab) for Second Quarter of 2018
July 17, 2018 06:50 ET
|
Genmab A/S
Company Announcement Net sales of DARZALEX in the second quarter of 2018 totaled USD 511 millionGenmab will receive royalties on worldwide net sales from Janssen Biotech, Inc. ...
Genmab Enters Strategic Partnership with Immatics to Discover and Develop Next Generation Bispecific Cancer Immunotherapies
July 12, 2018 01:56 ET
|
Genmab A/S
Company Announcement Genmab gains exclusive access to multiple novel proprietary tumor targets identified by Immatics Biotechnologies’ XPRESIDENT® technologyCreation of novel...
Capital Increase in Genmab as a Result of Employee Warrant Exercise
July 03, 2018 12:45 ET
|
Genmab A/S
Company Announcement Copenhagen, Denmark; July 3, 2018 – Genmab A/S (Nasdaq Copenhagen: GEN) will increase its share capital by 24,025 shares as a consequence of the exercise of...
HuMax®-AXL-ADC Progress Triggers Milestone Payment to Seattle Genetics
June 29, 2018 10:19 ET
|
Genmab A/S
Company Announcement Genmab to pay Seattle Genetics, Inc. a milestone payment of USD 7 million under the Antibody-Drug Conjugate (ADC) program targeting AXL Milestone triggered...
Grant of Restricted Stock Units and Warrants to Genmab employees
June 07, 2018 14:31 ET
|
Genmab A/S
Company Announcement Copenhagen, Denmark; June 7, 2018 – Genmab A/S (Nasdaq Copenhagen: GEN) announced today that at a board meeting the board decided to grant 5,305 restricted stock units and 14,714...
Genmab to Present at the Goldman Sachs 39th Annual Global Healthcare Conference
May 29, 2018 10:38 ET
|
Genmab A/S
Media Release Copenhagen, Denmark; May 29, 2018 – Genmab A/S (Nasdaq Copenhagen: GEN) announced today that its CEO, Jan van de Winkel, Ph.D., will present a company update at the...
Genmab Announces that Janssen Will Stop Studies of Daratumumab in Combination with Anti-PD-(L)1
May 26, 2018 03:55 ET
|
Genmab A/S
Company Announcement Based on a recent planned review, the Data Monitoring Committee (DMC) recommends Phase Ib/II study of daratumumab plus atezolizumab (anti PD-L1 antibody) in patients with...
Genmab Announces Topline Results in Phase III study of Arzerra® in Indolent Non-Hodgkin’s Lymphoma
May 24, 2018 10:20 ET
|
Genmab A/S
Company Announcement Topline results from Phase III study in iNHL did not meet primary endpoint of improved progression-free survival Copenhagen, Denmark; May 24, 2018 – Genmab A/S...